Prostate Cancer News: Breaking Prostate Cancer News, Comments and Articles. - Page: 5

New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology research

Lund, Sweden, May 16, 2013, Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data from two of its oncology projects, the drug candidates tasquinimod for the treatment of prostate cancer and ANYARA for the treatment of renal cell cancer, at the scientific conference "2013 ASCO Annual Meeting" to be held in Chicago (USA) on May 31- June 4, 2013. Active Biotech's collaboration pa...

Algeta ASA : New data and analyses from clinical trials of Xofigo® (radium-223 dichloride) to be presented at ASCO

Not Intended for US Media  Oslo, Norway, 16 May 2013 - Algeta ASA (OSE: ALGETA) announces that further analyses of data subsets from the phase III ALSYMPCA study of the recently FDA-approved Xofigo® (radium 223 dichloride, radium 223) will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), 31 May-4 June, in Chicago, IL (USA). Hematologic safety of...

Instaflex™ Joint Support Now Available In Walgreens Stores Nationwide

CHARLOTTE, N.C., May 16, 2013 /PRNewswire/ -- Direct Digital, LLC, the creator and marketer of one of the nation's leading nutritional supplements, Instaflex™ Joint Support, announced earlier this week the product is now being carried in Walgreens retail stores across the United States.  Direct Digital also sells Beneflex® Joint Relief, Nugenix™ Natural Testosterone Boos...

Study underscores new paradigm in cancer therapy

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate...

Finding targets prostate patients who would not benefit from cancer-detecting biopsy

UC Irvine Health urologists and health policy experts report in a new study that two written assessments that identify existing comorbidities - the patient-reported Total Illness Burden Index for Prostate Cancer (TIBI-Cap) and the physician-reported...

Prostate cancer drug Xofigo gets FDA approval

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.

FDA Approves Xofigo for Advanced Prostate Cancer

May 15, 2013 -- The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is....

Androgen Deprivation Therapy For Prostate Cancer Can Cause Osteoporosis

Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment. A new study¹ by Vahakn Shahinian and Yong-Fang...

Algeta ASA: New data and analyses from clinical trials of Xofigo(R) (radium Ra 223 dichloride) to be presented at ASCO

OSLO, NORWAY -- (Marketwired) -- 05/16/13 -- Intended for US Media only Algeta ASA (OSE: ALGETA) announces that further analyses of data subsets from the phase III ALSYMPCA study of the recently FDA-approved Xofigo® (radium Ra 223 dichloride, radium 223) will be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO),31 May-4 June, in Chicago, IL (USA). Hemat...

Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT

MONTREAL, QUEBEC -- (Marketwired) -- 05/16/13 -- Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies, announced today that the Company has been granted United States Patent No. 8,426,562 covering methods of treating carcinomas with antibodies targeting the region of secreted clusterin (sCLU) responsible for promoti...

New Information About the da Vinci Surgical Robot and What May Have Caused Hysterectomy and Prostate Surgery Complications Highlighted by The Onder Law Firm

Da Vinci robot surgery injury attorneys point to a bullet issued by Intuitive Surgical, Inc., the maker of the da Vinci robot, as evidence that a defect existed in the da Vinci Surgical Robot that has led to numerous complications when used in hysterectomy and prostate surgeries. St. Louis, MO (PRWEB) May 15, 2013 The Onder Law Firm, which is handling da Vinci robot surgery injury cases nationwid...

Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting, which is taking place May 31 – June 4 in Chicago. GALAXY-1 interim results “A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel vers...

Da Vinci Surgical Robot Injury Website Launched by Parker Waichman LLP to Help Update the Public on Latest Developments

The national law firm is offering legal evaluations to anyone who allegedly suffered a serious, life-threatening injury following a da Vinci robot-assisted operation, which would include prostate removal, hysterectomies and gall bladder surgery, among other procedures. The newly launched da Vinci website will assist the firm in these efforts by helping potential victims of the device obtain additi...

Bayer's radiation prostate cancer drug bags US nod

Bayer's radiation prostate cancer drug bags US nod

Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting

-- Exelixis to host investor briefing via live webcast on Sunday, June 2, 2013 Exelixis, Inc. (NASDAQ:EXEL) reiterated its slate of activities in conjunction with the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2013, in Chicago, Illinois. Clinical data from cabozantinib will be the subject of nine...

Bayer to Present New Data Across Oncology Portfolio at ASCO 2013

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product Xofigo® (radium Ra 223 dichloride) injection will be presented at the 49th Annual...

Janssen Oncology Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Including ZYTIGA®, Ibrutinib and Daratumumab Data

RARITAN, N.J., May 15, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen Oncology compounds have been selected for presentation at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2013 in Chicago, IL. Fourteen abstracts for ZYTIGA® (abiraterone acetate), ibrutinib, the invest...

Genomic Health's New Prostate Test May Extend The Stock's Upward Climb

By Amy Baldwin:Genomic Health, Inc.'s (GHDX) stock has risen over 31% in the last month. The molecular diagnostics company's upward swing may be due to an earlier announcement of an 8% increase in revenue, but what probably propelled the stock further in the last few days was that Genomic health announced its novel genetic test to gauge the aggressiveness of prostate cancer became available on the...

Tokai raises $35.5 million in E round

Tokai Pharmaceuticals Inc. (Cambridge, Mass.) raised $35.5 million in a series E round from existing investors Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors. Tokai's galeterone is in the Phase II ARMOR2 trial...

FDA approves radium-223 from Bayer, Algeta

FDA approved an NDA from Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat castration-resistant prostate cancer (CRPC) in patients with symptomatic bone metastases. Xofigo is indicated for men whose cancer has spread after receiving med...

Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA

Not Intended for US Media New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases  Xofigo shown in a pivotal phase III trial to significantly improve overall survival  Algeta to host international conference call scheduled for tomorrow at 08:00 CET - details below  Oslo, Norway, 15 May 2013 - Algeta ASA (OSE: ALGETA) announces that the US Food and...

Bayer/Algeta’s Xofigo Brings New Mechanism To Prostate Cancer Field

FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.

Bayer Gets FDA Approval for Advanced Prostate Cancer Drug

Federal regulators approved a new drug Wednesday from Bayer to treat certain types of advanced prostate cancer.

Lower Urinary Tract Symptoms Caused by BPH Can Be Improved with Thermobalancing Therapy without Potentially Harmful Drugs & Prostate Surgeries, States Fine Treatment

An enlarged prostate can cause urination problems in men, states the latest article in Time-Leader. At the same time Thermobalancing therapy is effective at improving BPH symptoms which comes gradually by decreasing the size of the enlarged prostate naturally, highlights Fine Treatment. London, UK (PRWEB) May 15, 2013 It is typical that the users of Dr. Allen’s Device for Prostate Care experien...

US approves radiation-based prostate cancer drug

(AP)—The U.S. Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones.